About
Our Story
Our People
Our Advisors
Science
Pipeline
Izokibep
Lonigutamab
SLRN-517
Presentations & Publications
Community
Patients
Partnerships
Investors & Media
Overview
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Email Alerts
Investor Resources
Media Resources
Careers
Stories
Contact Us
Presentation
Achievement of Different Treatment Targets with Izokibep in Psoriatic Arthritis at 16- and 46-Weeks
November 7, 2022
Share
Achievement of Different Treatment Targets with Izokibep in Psoriatic Arthritis at 16- and 46-Weeks
Copy
